Targets › DPP4
19 programs from 18 companies in 30 trials: 12 Phase 3, 9 Phase 1, 5 Phase 4, 4 Phase 2; Metabolic and endocrine, Oncology, Cardiovascular; next expected readout Nov 2026.
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. (UniProt, P27487)
Open in Phaseline: the race on DPP4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Huazhong University of Science and Technology | Cofrogliptin DPP-4 inhibitor | DPP4 | Phase 4 | T2DM | Dec 2026 |
| JW Pharmaceutical | Anagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 4 | Type 2 Diabetes Mellitus (T2DM) | Mar 2027 |
| Tanta University | Sitagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 4 | Breast Cancer | Nov 2027 |
| Nabiqasim Industries (Pvt) | Linagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 4 | Diabetes Mellitus | – |
| University of Pennsylvania | Sitagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 4 | Genetics Disease | – |
| CSPC Ouyi Pharmaceutical | Prusogliptin Dipeptidyl peptidase-4 inhibitor | DPP4 | Phase 3 | Type 2 Diabetes | Nov 2026 |
| AstraZeneca | Elecoglipron Dipeptidyl peptidase-4 (DPP-4) inhibitor | DPP4, GCK, GCGR | Phase 3 | Obesity; Type 2 Diabetes Mellitus; Weight Management; Heart Failure With Preserved Ejection Fraction (HFpEF) … | Nov 2026 |
| Sherief Abd-Elsalam | Vildagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 3 | dm | Dec 2028 |
| Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | Saxagliptin Hydrochloride Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 2 | Type 2 Diabetes | Nov 2026 |
| Case Comprehensive Cancer Center | Sitagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 2 | Glioblastoma | Jun 2027 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Sitagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 2 | Bladder Urothelial Carcinoma | Jun 2028 |
| October 6 University | Vildagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 2 | Poly Cystic Ovary Syndrome | – |
| Eric Stephen Winer, MD | BXCL701 Dipeptidyl peptidase-4 (DPP4) inhibitor | DPP4 | Phase 1 | Acute Myeloid Leukemia | Dec 2026 |
| Fernando Maciel Barbosa | Sitagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 1 | Advanced Renal Cell Carcinoma | Apr 2028 |
| Kailin Yang, MD, PhD | Sitagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 1 | Glioma | Jun 2029 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Sitagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 1 | Colorectal Cancer | Dec 2029 |
| Northwell Health | Sitagliptin Dipeptidyl peptidase IV inhibitor | DPP4 | Phase 1 | GVHD - Graft-Versus-Host Disease | Jul 2030 |
| University of Yaounde 1 | Cissus quadrangularis extract (CQE) DPP-4 inhibition and GLP-1 elevation | DPP4 | Phase 1 | Obesity and Overweight | – |
| University of Yaounde 1 | Dichrostachys glomerata extract (DGE) DPP-4 inhibition and GLP-1 elevation | DPP4 | Phase 1 | Obesity and Overweight | – |
Type 2 Diabetes Mellitus (5) Healthy Participants (2) Type 2 Diabetes (2) dm (2) Obesity and Overweight (2) Poly Cystic Ovary Syndrome (1) Glioblastoma (1) Obesity (1) Weight Management (1) Heart Failure With Preserved Ejection Fraction (HFpEF) (1) Chronic Kidney Disease (1) Glioma (1)
small molecule (12), mixed (6)
University of Yaounde 1 (2) October 6 University (1) Case Comprehensive Cancer Center (1) AstraZeneca (1) Kailin Yang, MD, PhD (1) Eric Stephen Winer, MD (1) CSPC Ouyi Pharmaceutical (1) Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair (1) Nabiqasim Industries (Pvt) (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Sherief Abd-Elsalam (1) Tanta University (1) Huazhong University of Science and Technology (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) University of Pennsylvania (1) Northwell Health (1) JW Pharmaceutical (1) Fernando Maciel Barbosa (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.